Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Silencing prostate cancer

Systemic delivery of an siRNA–aptamer chimera leads to prostate cancer regression in mice.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Strategies for systemic delivery of siRNA.


  1. 1

    Whitehead, K.A., Langer, R. & Anderson, D.G. Nat. Rev. Drug Discov. 8, 129–138 (2009).

    CAS  Article  Google Scholar 

  2. 2

    Dassie, J.P. et al. Nat Biotechnol. 27, 839–846 (2009).

    CAS  Article  Google Scholar 

  3. 3

    McNamara, J.O. et al. Nat. Biotechnol. 24, 1005–1015 (2006).

    CAS  Article  Google Scholar 

  4. 4

    Zimmermann, T.S. et al. Nature 441, 111–114 (2006).

    CAS  Article  Google Scholar 

  5. 5

    Akinc, A. et al. Nat. Biotechnol. 26, 561–569 (2008).

    CAS  Article  Google Scholar 

  6. 6

    Frank-Kamenetsky, M. et al. Proc. Natl. Acad. Sci. USA 105, 11915–11920 (2008).

    CAS  Article  Google Scholar 

  7. 7

    Judge, A.D. et al. J. Clin. Invest. 119, 661–673 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Peer, D. et al. Science 319, 627–630 (2008).

    CAS  Article  Google Scholar 

  9. 9

    Rozema, D.B. et al. Proc. Natl. Acad. Sci. USA 104, 12982–12987 (2007).

    CAS  Article  Google Scholar 

  10. 10

    Hu-Lieskovan, S. et al. Cancer Res 65, 8984–8992 (2005).

    CAS  Article  Google Scholar 

  11. 11

    Soutschek, J. et al. Nature 432, 173–178 (2004).

    CAS  Article  Google Scholar 

  12. 12

    Chu, T.C., Twu, K.Y., Ellington, A.D. & Levy, M. Nucleic Acids Res. 34, e73 (2006).

    Article  Google Scholar 

  13. 13

    Zhou, J. et al. Mol. Ther. 16, 1481–1489 (2008).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Antonin de Fougerolles.

Ethics declarations

Competing interests

A.D.F. and I.T. are employees of Alnylam Pharmaceuticals, a company engaged in the development of RNAi therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Toudjarska, I., de Fougerolles, A. Silencing prostate cancer. Nat Biotechnol 27, 821–823 (2009).

Download citation

Further reading


Quick links